You are here

Letter to the Editor

Medications for Parkinson’s Disease

Richard P. Hoffmann PharmD

To the Editor:

As a pharmacist and care partner for my wife who has Parkinson’s disease (PD), I would like to offer the following comments regarding the “Pipeline Plus” feature in P&T (October 2014, pages 712–713) entitled “Steady Progress on Parkinson’s Disease.” This well-intentioned article has two errors/omissions that I would like to point out to your readers.

With regard to the dosage regimen for ropinirole (Requip) in PD: After initial titration, the typical treatment regimen for Parkinson’s disease is 9–24 mg total daily dose (divided three to four times daily).1

In addition, the monoamine oxidase-B (MAO-B) inhibitor selegiline was not included in the table of current therapies. This MAO-B inhibitor has been available for many years and is at least one-tenth the cost of rasagiline (Azilect) but is equally effective.2

I believe that this additional information is important for pharmacists working with PD patients to know.


  1. In: Houghton D, Hurtig H. Parkinson’s Disease: Medications 5th ed.Miami, Florida: National Parkinson Foundation. 2008;6
  2. Hoffmann RP. Selegiline and rasagiline: twins or distant cousins? (Letter). Consult Pharm 2011;26;(5):294